Imagabalin
Clinical data | |
---|---|
Other names | PD-0332334; PD-332,334 |
ATC code |
|
Identifiers | |
| |
JSmol) | |
| |
|
Imagabalin (
phase-III clinical trials for treatment of generalized anxiety disorder; however, the trials were terminated by the manufacturer.[3][4][5][6]
The drug is no longer under development.
See also
- Atagabalin
- PD-217,014
- Gabapentinoids
References
- PMID 21664606.
- ^ Larry Ereshefsky (2008). "Therapies in the Pipeline for Sleep Disorders: Focus on Novel Mechanisms and Disease Models" (PDF) (Press release). p. 11. Retrieved 2012-04-22.
- ^ Pfizer (2012-11-09). "A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study Of PD 0332334 And Paroxetine Evaluating The Efficacy And Safety Of PD 0332334 For The Treatment Of Generalized Anxiety Disorder".
{{cite journal}}
: Cite journal requires|journal=
(help) - ^ Pfizer (2012-11-09). "A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study Of PD 0332334 And Paroxetine Evaluating The Efficacy And Safety Of PD 0332334 For The Treatment Of Generalized Anxiety Disorder".
{{cite journal}}
: Cite journal requires|journal=
(help) - ^ Pfizer (2012-11-09). "A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study of PD 0332334 and Paroxetine Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder".
{{cite journal}}
: Cite journal requires|journal=
(help) - ^ Pfizer (2012-11-09). "A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder".
{{cite journal}}
: Cite journal requires|journal=
(help)